Report cover image

Cancer Anorexia-Cachexia Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Global Markets Direct
Published May 31, 2022
Length 147 Pages
SKU # GMD17226468

Description

Cancer Anorexia-Cachexia Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Anorexia-Cachexia Syndrome - Drugs In Development, 2022, provides an overview of the Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline landscape.

Cancer anorexia-cachexia syndrome is defined as progressive weight loss associated with malignancy and is characterized by loss of appetite (anorexia), skeletal muscle wasting, and reduced adipose tissue. Approximately 50% of cancer patients report abnormalities of eating behavior at the time of first diagnosis and prevalence is even higher at approximately 65%. The incidence of weight loss upon diagnosis varies greatly according to the tumor site.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Anorexia-Cachexia Syndrome - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cancer Anorexia-Cachexia Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages are 1, 5, 2, 1, 15 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Anorexia-Cachexia Syndrome (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

147 Pages
Introduction
Global Markets Direct Report Coverage
Cancer Anorexia-Cachexia Syndrome – Overview
Cancer Anorexia-Cachexia Syndrome – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cancer Anorexia-Cachexia Syndrome – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cancer Anorexia-Cachexia Syndrome – Companies Involved in Therapeutics Development
AAVogen Inc
Abreos Biosciences Inc
Actimed Therapeutics Ltd
Aeterna Zentaris Inc
Aphios Corp
Artelo Biosciences Inc
AtoGen Co Ltd
AVEO Pharmaceuticals Inc
Betula Pharma
Byomass Inc
Cannabics Pharmaceuticals Inc
Creative Medical Technology Holdings Inc
Endevica Bio
Extend Biosciences Inc
FibroGenesis LLC
Helsinn Group
Immuneering Corp
Larix Bioscience LLC
MGC Pharmaceuticals Ltd
NGM Biopharmaceuticals Inc
Oncocross Co Ltd
Oneness Biotech Co Ltd
Paradigm Biopharmaceuticals Ltd
Pfizer Inc
RaQualia Pharma Inc
Signablok Inc
Vascular BioSciences
Zeria Pharmaceutical Co Ltd
Cancer Anorexia-Cachexia Syndrome – Drug Profiles
(cannabidiol + dronabinol) Sustained Release – Drug Profile
ACM-001 – Drug Profile
AmnioStem – Drug Profile
anamorelin hydrochloride – Drug Profile
Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia – Drug Profile
ART-27.13 – Drug Profile
AV-380 – Drug Profile
AVGN-7 – Drug Profile
Bi-Specific Antibodies To Inhibit GDF-15 – Drug Profile
CAR Peptide – Drug Profile
dronabinol – Drug Profile
EXT-418 – Drug Profile
FB-704A – Drug Profile
Fusion Protein to Inhibit Activin A for Cancer Cachexia and Osteoporosis – Drug Profile
IP-1510 – Drug Profile
LABthera-002 – Drug Profile
macimorelin acetate – Drug Profile
Monoclonal Antibody to Inhibit GDF15 for Cancer Anorexia-Cachexia Syndrome – Drug Profile
NGM-120 – Drug Profile
OC-514 – Drug Profile
ponsegromab – Drug Profile
Recombinant Peptide to Inhibit CIDEA for Cancer Cachexia – Drug Profile
RQ-00433412 – Drug Profile
Small Molecules for Cancer Induced Cachexia and Immunology – Drug Profile
Small Molecules to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes – Drug Profile
Small Molecules to Inhibit KRAS for Cancer Cachexia – Drug Profile
Synthetic Peptides for Cancer Cachexia – Drug Profile
TBCV-92 – Drug Profile
TCMCB-07 – Drug Profile
Tetrinol – Drug Profile
TMS-008 – Drug Profile
Z-505 – Drug Profile
Cancer Anorexia-Cachexia Syndrome – Dormant Projects
Cancer Anorexia-Cachexia Syndrome – Discontinued Products
Cancer Anorexia-Cachexia Syndrome – Product Development Milestones
Featured News & Press Releases
May 04, 2022: Actimed Therapeutics secures significant new patent, extending IP coverage of its lead compound for use in key indication
Dec 14, 2021: Actimed Therapeutics achieves major corporate milestone - initiation of first clinical study of new salt of S-pindolol (ACM-001.1)
Aug 31, 2021: Endevica Bio reports TCMCB07 preserves lean body mass in preclinical cancer cachexia study
Apr 07, 2021: Endevica Bio begins IND-enabling toxicology studies
Feb 08, 2021: FDA grants Breakthrough Device Designation for Roche's Elecsys growth differentiation factor-15 (GDF-15) assay to help identify patients suitable for innovative treatment addressing unintentional weight loss in cancer patients
Feb 02, 2021: Actimed Therapeutics appoints Frank Misselwitz MD, PhD as chief medical officer
Jan 22, 2021: ONO receives a manufacturing and marketing approval of Adlumiz (anamorelin), a ghrelin receptor agonist for the treatment of cancer cachexia in Japan
Mar 07, 2019: Helsinn initiates two new global Phase III studies with anamorelin
Sep 12, 2018: Extend Biosciences receives an SBIR supplemental award
Mar 05, 2018: Aeterna Zentaris Provides Update on Previously Disclosed Class Action Lawsuit
Sep 15, 2017: Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)
May 18, 2017: Helsinn Announces Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)
Apr 24, 2017: Extend Biosciences Is Awarded A Phase II SBIR Grant From NCI
Feb 13, 2017: Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen
Sep 30, 2016: TCI Peptide Therapeutics awarded NIH grant
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Universities/Institutes, 2022
Table 5: Products under Development by Companies, 2022
Table 6: Products under Development by Companies, 2022 (Contd..1)
Table 7: Products under Development by Universities/Institutes, 2022
Table 8: Number of Products by Stage and Target, 2022
Table 9: Number of Products by Stage and Mechanism of Action, 2022
Table 10: Number of Products by Stage and Route of Administration, 2022
Table 11: Number of Products by Stage and Molecule Type, 2022
Table 12: Cancer Anorexia-Cachexia Syndrome – Pipeline by AAVogen Inc, 2022
Table 13: Cancer Anorexia-Cachexia Syndrome – Pipeline by Abreos Biosciences Inc, 2022
Table 14: Cancer Anorexia-Cachexia Syndrome – Pipeline by Actimed Therapeutics Ltd, 2022
Table 15: Cancer Anorexia-Cachexia Syndrome – Pipeline by Aeterna Zentaris Inc, 2022
Table 16: Cancer Anorexia-Cachexia Syndrome – Pipeline by Aphios Corp, 2022
Table 17: Cancer Anorexia-Cachexia Syndrome – Pipeline by Artelo Biosciences Inc, 2022
Table 18: Cancer Anorexia-Cachexia Syndrome – Pipeline by AtoGen Co Ltd, 2022
Table 19: Cancer Anorexia-Cachexia Syndrome – Pipeline by AVEO Pharmaceuticals Inc, 2022
Table 20: Cancer Anorexia-Cachexia Syndrome – Pipeline by Betula Pharma, 2022
Table 21: Cancer Anorexia-Cachexia Syndrome – Pipeline by Byomass Inc, 2022
Table 22: Cancer Anorexia-Cachexia Syndrome – Pipeline by Cannabics Pharmaceuticals Inc, 2022
Table 23: Cancer Anorexia-Cachexia Syndrome – Pipeline by Creative Medical Technology Holdings Inc, 2022
Table 24: Cancer Anorexia-Cachexia Syndrome – Pipeline by Endevica Bio, 2022
Table 25: Cancer Anorexia-Cachexia Syndrome – Pipeline by Extend Biosciences Inc, 2022
Table 26: Cancer Anorexia-Cachexia Syndrome – Pipeline by FibroGenesis LLC, 2022
Table 27: Cancer Anorexia-Cachexia Syndrome – Pipeline by Helsinn Group, 2022
Table 28: Cancer Anorexia-Cachexia Syndrome – Pipeline by Immuneering Corp, 2022
Table 29: Cancer Anorexia-Cachexia Syndrome – Pipeline by Larix Bioscience LLC, 2022
Table 30: Cancer Anorexia-Cachexia Syndrome – Pipeline by MGC Pharmaceuticals Ltd, 2022
Table 31: Cancer Anorexia-Cachexia Syndrome – Pipeline by NGM Biopharmaceuticals Inc, 2022
Table 32: Cancer Anorexia-Cachexia Syndrome – Pipeline by Oncocross Co Ltd, 2022
Table 33: Cancer Anorexia-Cachexia Syndrome – Pipeline by Oneness Biotech Co Ltd, 2022
Table 34: Cancer Anorexia-Cachexia Syndrome – Pipeline by Paradigm Biopharmaceuticals Ltd, 2022
Table 35: Cancer Anorexia-Cachexia Syndrome – Pipeline by Pfizer Inc, 2022
Table 36: Cancer Anorexia-Cachexia Syndrome – Pipeline by RaQualia Pharma Inc, 2022
Table 37: Cancer Anorexia-Cachexia Syndrome – Pipeline by Signablok Inc, 2022
Table 38: Cancer Anorexia-Cachexia Syndrome – Pipeline by Vascular BioSciences, 2022
Table 39: Cancer Anorexia-Cachexia Syndrome – Pipeline by Zeria Pharmaceutical Co Ltd, 2022
Table 40: Cancer Anorexia-Cachexia Syndrome – Dormant Projects, 2022
Table 41: Cancer Anorexia-Cachexia Syndrome – Dormant Projects, 2022 (Contd..1)
Table 42: Cancer Anorexia-Cachexia Syndrome – Dormant Projects, 2022 (Contd..2)
Table 43: Cancer Anorexia-Cachexia Syndrome – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Top 10 Targets, 2022
Figure 4: Number of Products by Stage and Top 10 Targets, 2022
Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Routes of Administration, 2022
Figure 8: Number of Products by Stage and Routes of Administration, 2022
Figure 9: Number of Products by Molecule Types, 2022
Figure 10: Number of Products by Stage and Top 10 Molecule Types, 2022

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us